The central theme of Project Ib has been the generation, characterization and application of defined monoclonal antibody (Mab) reagents with anti-glioma reactivity in both in vitro and in vivo settings. Interacting with projects Ia, Ic, the core facilities Ia1, Ib1, and Ic1, IIb, and IVb, Project Ib has as specific aims: 1. Generation of anti-epidermal growth factor receptor (EGFR) murine Mabs vs. both the well-characterized A431 squamous cell carcinoma cell line EGFR and glioma-expressed EGFR for use in vitro (immunohistological, growth control studies) and in vivo (localizing, model immunotherapeutic) applications. With project Ic, Mabs will be prepared using the A431 cell line as source of EGFR; different immunization protocols incorporating trypsinized cells, combination protocols of cells and EGF-affinity purified A431 cell membrane preparations, and gel isolated 170 Kd EGFR-enriched bands will be performed. Optimal method(s) identified will be used to produce Mabs to glioma-associated EGFR. 2. Analysis of the Mab 81C6-defined extracellular matrix antigen tenascin (formerly GMEM) at the genetic, epitopic, molecular, and functional levels, and extended studies of the use of tenascin as a localizable target is the most advanced and extensive aim of Project Ib. Given our established procedures for Mab 81C6 affinity purification of tenascin, we will affinity purify enzymatically cleaved tenascin fragments reactive with anti-tenascin reagents, including polyvalent rabbit and macaque sera, murine Mabs, and serum samples obtained from immunotherapy patients. Reactive polypeptides will undergo epitope restriction analysis, amino acid sequencing, and serve as immunogens for directed immunization vs. epitopes of evolutionarily conserved, organotypic, and potentially fetal brain-glioma restricted expression. Expression clones from a lambdal gt 11 library produced by Dr. Mario Bourdon also will be screened and used to define the genomic profile of tenascin. With Project IIb, the differential capacities of restricted epitope Mabs and their fragments will be assessed in both subcutaneous and intracranial xenograft localization studies. 3. Three new glioma- associated, localizable antigens, C12, D12, and E9 will be developed for potential in vivo application following successful tenascin protocols: affinity purification of antigen, production of second generation Mabs, and Mab fragments for localization studies. 4. Recent data obtained in this laboratory suggest possible phenotypic markers for glial vs. neuronal differentiation pathways in medulloblastoma (Mab); we propose to generate Mabs to the unique bank of four established MED cell lines maintained at Duke, and a fifth available in xenograft form. In conjunction with project IVb, these studies will form the basis for complete phenotypic investigation of medulloblastoma parallel to that ongoing in glioma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS020023-06
Application #
3902038
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Slastnikova, Tatiana A; Rosenkranz, Andrey A; Zalutsky, Michael R et al. (2015) Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des 21:1227-38
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Brown, Michael C; Dobrikova, Elena Y; Dobrikov, Mikhail I et al. (2014) Oncolytic polio virotherapy of cancer. Cancer 120:3277-86
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29

Showing the most recent 10 out of 146 publications